HC Wainwright Has Bullish Forecast for BCTX Q1 Earnings

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a research note issued on Monday, December 2nd. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $0.24 EPS.

BriaCell Therapeutics Stock Performance

Shares of BCTX stock opened at $1.01 on Thursday. The stock’s fifty day moving average is $0.84 and its 200-day moving average is $0.91. The stock has a market capitalization of $36.54 million, a PE ratio of -0.86 and a beta of 1.46. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.